X4 Pharmaceuticals, Inc.
XFOR
$3.70
-$0.18-4.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.75% | -128.34% | 100.54% | -108.16% | -1,492.02% |
| Total Depreciation and Amortization | -16.48% | 82.99% | 667.74% | 340.32% | 156.73% |
| Total Amortization of Deferred Charges | 13.92% | 2.42% | -11.42% | -18.95% | -20.16% |
| Total Other Non-Cash Items | -44.20% | 99.58% | -163.89% | 244.47% | 117.23% |
| Change in Net Operating Assets | 63.47% | -501.53% | -256.94% | 122.32% | -146.86% |
| Cash from Operations | 18.25% | 1.24% | 63.19% | -18.91% | -63.40% |
| Capital Expenditure | -- | -- | -- | -17.14% | -1,050.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81.03% | 388.76% | 40.38% | -78.82% | -207.57% |
| Cash from Investing | -79.98% | -76.14% | 41.04% | -78.38% | -208.88% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 3,441.51% | -- | 39.18% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -72.07% | -- | 39.18% | -100.00% |
| Foreign Exchange rate Adjustments | -100.61% | 872.22% | 222.03% | -292.13% | 329.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 161.08% | -101.17% | 60.40% | -28.96% | -926.30% |